Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies

Overview of attention for article published in Journal of Hematology & Oncology, November 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 18 Dimensions

Readers on

mendeley: 30 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,562 followers.

An important application for targeted radiopharmaceuticals: compartmental delivery for CNS malignancies (e.g. leptomeningeal disease).

17 Nov 2022

Reply Repost Favourite

"Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies" showing that cRIT targeting B7H3 was safe and could be used in patients with leptomeningeal malignancies.- now out in Journal of Hematology & Oncolog

17 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.